Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Open access
Gallais, Floriane, Gantner, Pierre, Bruel, Timothée, Velay, Aurélie, Planas, Delphine, Wendling, Marie-Josée, Bayer, Sophie, Solis, Morgane, Laugel, Elodie, Reix, Nathalie, Schneider, Anne, Glady, Ludovic, Panaget, Baptiste, Collongues, Nicolas, Partisani, Marialuisa, Lessinger, Jean-Marc, Fontanet, Arnaud, Rey, David, Hansmann, Yves, Kling-Pillitteri, Laurence, Schwartz, Olivier, De Sèze, Jérome, Meyer, Nicolas, Gonzalez, Maria, Schmidt-Mutter, Catherine, Fafi-Kremer, Samira·2021·eBioMedicine

Published version of a preprint

Abstract

BACKGROUND: Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting risk of reinfection and durability of vaccine protection. METHODS: This is a prospective, monocentric, longitudinal, cohort clinical study. Healthcare workers (HCW) from Strasbourg University Hospital were enrolled between April 6th and May 7th, 2020 and followed up to 422 days. Serial serum samples were tested for antibodies against the Receptor Binding Domain (RBD) of the spike protein and nucleocapsid protein (N) to characterize the kinetics of SARS-CoV-2 antibodies and the incidence of reinfection. Live-neutralization assays were performed for a subset of samples before and after vaccination to analyze sensitivity to SARS-CoV-2 variants. FINDINGS: A total of 4290 samples from 393 convalescent COVID-19 and 916 COVID-19 negative individuals were analyzed. In convalescent individuals, SARS-CoV-2 antibodies followed a triphasic kinetic model with half-lives at month (M) 11-13 of 283 days (95% CI 231-349) for anti-N and 725 days (95% CI 623-921) for anti-RBD IgG, which stabilized at a median of 1.54 log BAU/mL (95% CI 1.42-1.67). The incidence of SARS-CoV-2 infections was 12.22 and 0.40 per 100 person-years in COVID-19-negative and COVID-19-positive HCW, respectively, indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7%. Live-virus neutralization assay revealed that after one year, variants D614G and B.1.1.7, but less so B.1.351, were sensitive to anti-RBD antibodies at 1.4 log BAU/mL, while IgG ≥ 2.0 log BAU/mL strongly neutralized all three variants. These latter anti-RBD IgG titers were reached by all vaccinated HCW regardless of pre-vaccination IgG levels and type of vaccine. INTERPRETATION: Our study demonstrates a long-term persistence of anti-RBD antibodies that may reduce risk of reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against variants. FUN1DING: None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2021.103561

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 239

Metadata

Authors
Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., Schneider, A., Glady, L., Panaget, B., Collongues, N., Partisani, M., Lessinger, J.-M., Fontanet, A., Rey, D., Hansmann, Y., Kling-Pillitteri, L., Schwartz, O., De Sèze, J., Meyer, N., Gonzalez, M., Schmidt-Mutter, C., & Fafi-Kremer, S.
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2021-09
Volume
71
Pages
103561
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3193970389
Cited by
239
References
18
FWCI
16.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. https://app.cochat.ai/papers/10.1016/j.ebiom.2021.103561
The paper
Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., Schneider, A., Glady, L., Panaget, B., Collongues, N., Partisani, M., Lessinger, J.-M., Fontanet, A., Rey, D., Hansmann, Y., . . . Fafi-Kremer, S. (2021). Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. eBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.